JP6731405B2 - ウイルス粒子を用いた癌免疫療法 - Google Patents

ウイルス粒子を用いた癌免疫療法 Download PDF

Info

Publication number
JP6731405B2
JP6731405B2 JP2017524349A JP2017524349A JP6731405B2 JP 6731405 B2 JP6731405 B2 JP 6731405B2 JP 2017524349 A JP2017524349 A JP 2017524349A JP 2017524349 A JP2017524349 A JP 2017524349A JP 6731405 B2 JP6731405 B2 JP 6731405B2
Authority
JP
Japan
Prior art keywords
cancer
tumor
ecpmv
lung
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017524349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533920A5 (enExample
JP2017533920A (ja
Inventor
エフ． シュタインメッツ，ニコル
エフ． シュタインメッツ，ニコル
エム． ウェン，エイミー
エム． ウェン，エイミー
フィーリング，スティーブン
エイチ． リゾッテ，パトリック
エイチ． リゾッテ，パトリック
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
ケース ウエスタン リザーブ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ, ケース ウエスタン リザーブ ユニバーシティ filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2017533920A publication Critical patent/JP2017533920A/ja
Publication of JP2017533920A5 publication Critical patent/JP2017533920A5/ja
Application granted granted Critical
Publication of JP6731405B2 publication Critical patent/JP6731405B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017524349A 2014-11-07 2015-11-09 ウイルス粒子を用いた癌免疫療法 Active JP6731405B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462076543P 2014-11-07 2014-11-07
US62/076,543 2014-11-07
US201562107617P 2015-01-26 2015-01-26
US62/107,617 2015-01-26
US201562159389P 2015-05-11 2015-05-11
US62/159,389 2015-05-11
PCT/US2015/059675 WO2016073972A1 (en) 2014-11-07 2015-11-09 Cancer immunotherapy using virus particles

Publications (3)

Publication Number Publication Date
JP2017533920A JP2017533920A (ja) 2017-11-16
JP2017533920A5 JP2017533920A5 (enExample) 2018-11-22
JP6731405B2 true JP6731405B2 (ja) 2020-07-29

Family

ID=55909946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017524349A Active JP6731405B2 (ja) 2014-11-07 2015-11-09 ウイルス粒子を用いた癌免疫療法

Country Status (7)

Country Link
US (4) US10639363B2 (enExample)
EP (2) EP3957644B1 (enExample)
JP (1) JP6731405B2 (enExample)
CN (1) CN107001428B (enExample)
AU (1) AU2015342790B2 (enExample)
CA (1) CA2967336C (enExample)
WO (2) WO2016073972A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086095B2 (en) 2012-10-09 2018-10-02 Case Western Reserve University Rod-shaped plant virus nanoparticles as imaging agent platforms
US11193111B2 (en) 2013-01-17 2021-12-07 Case Western Reserve University Viral nanoparticle multimers
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
US12465624B2 (en) 2018-05-08 2025-11-11 Case Western Reserve University Cancer immunotherapy using virus particles and immune checkpoint therapy
JP6731405B2 (ja) * 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
US11617787B2 (en) 2014-11-07 2023-04-04 Case Western Reserve University Cancer immunotherapy using virus particles
US10624975B2 (en) 2015-06-29 2020-04-21 Case Western Reserve University Anticancer drug-containing plant virus particles
US10478510B2 (en) 2015-07-16 2019-11-19 Case Western Resrve University Plant virus particles for delivery of antimitotic agents
US11433123B2 (en) 2016-07-21 2022-09-06 Case Western Reserve University Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer
AU2017354004C1 (en) 2016-11-03 2023-08-31 Case Western Reserve University Melt processed viral nanoparticle constructs
US12433840B2 (en) 2016-11-03 2025-10-07 Case Western Reserve University Melt processed viral nanoparticle constructs
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
WO2019084555A1 (en) 2017-10-27 2019-05-02 Case Western Reserve University TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS
WO2019173487A1 (en) * 2018-03-06 2019-09-12 University Of Louisville Research Foundation, Inc. Methods for treatment of cancer and enhancement of nanoparticle accumulation in tissues
JP7641005B2 (ja) * 2018-12-27 2025-03-06 ヴェリミューン インコーポレイテッド コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
US20220145316A1 (en) * 2019-03-01 2022-05-12 The Regents Of The University Of California Cancer immunotherapy
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
CN110859861A (zh) * 2019-12-04 2020-03-06 武汉工程大学 植物病原微生物杀灭癌细胞或艾滋病病毒的用途
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
US20240066108A1 (en) * 2021-01-08 2024-02-29 The Regents Of The University Of California Ovarian cancer vaccine
JP2025504361A (ja) * 2022-01-19 2025-02-12 ウニベルズィテート ベルン ウイルス様粒子と微結晶性チロシンとの組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004606A (en) 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
TWI438010B (zh) 2002-05-02 2014-05-21 Wyeth Corp 卡奇黴素（ｃａｌｉｃｈｅａｍｉｃｉｎ）衍生物-載體共軛物
CA2435632A1 (en) * 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
RU2006146605A (ru) 2004-06-02 2008-07-20 Цитос Биотехнологи Аг (Ch) Медицинские применения конъюгатов-носителей tnf-пептидов из организма кроме человека
WO2008048288A2 (en) 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
AU2006351933A1 (en) * 2005-12-02 2008-07-17 Dow Global Technologies Inc. Novel plant virus particles and methods of inactivation thereof
US7771339B2 (en) * 2006-05-31 2010-08-10 Ab Mimator Method and system for radiotherapy treatment
US20100183504A1 (en) 2007-06-14 2010-07-22 Fanqing Frank Chen Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
WO2016149264A1 (en) 2015-03-18 2016-09-22 The Johns Hopkins University Compositions and methods for sensitizing cells to trail-induced apoptosis
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
US20130236491A1 (en) 2010-12-09 2013-09-12 Iosif Grigorievich Atabekov Spherical nano and microparticles derived from plant viruses for the display of foreign proteins or epitopes
WO2013018155A1 (ja) 2011-07-29 2013-02-07 株式会社ユーテック 強誘電体膜およびその製造方法
WO2013158620A1 (en) 2012-04-16 2013-10-24 North Carolina State University Nanotechnology system for agricultural applications
CN109876139A (zh) 2012-04-24 2019-06-14 俄亥俄州国家创新基金会 用于治疗和预防猪繁殖与呼吸综合征的组合物和方法
US10232057B2 (en) 2012-05-31 2019-03-19 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
US10086095B2 (en) 2012-10-09 2018-10-02 Case Western Reserve University Rod-shaped plant virus nanoparticles as imaging agent platforms
US20160228541A1 (en) * 2013-09-19 2016-08-11 Alain Lamarre Papaya mosaic virus and virus-like particles in cancer therapy
WO2015188110A1 (en) 2014-06-05 2015-12-10 The Johns Hopkins University Reversible pegylation for screeing of therapeutic proteins in vivo
EP3174976B1 (en) 2014-08-01 2020-10-28 GPB Scientific, Inc. Methods and systems for processing particles
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
JP6731405B2 (ja) * 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
US10624975B2 (en) * 2015-06-29 2020-04-21 Case Western Reserve University Anticancer drug-containing plant virus particles
US10478510B2 (en) 2015-07-16 2019-11-19 Case Western Resrve University Plant virus particles for delivery of antimitotic agents
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles

Also Published As

Publication number Publication date
EP3215520A1 (en) 2017-09-13
AU2015342790A1 (en) 2017-06-08
US20230024508A1 (en) 2023-01-26
US20180133304A1 (en) 2018-05-17
JP2017533920A (ja) 2017-11-16
EP3957644B1 (en) 2024-08-07
EP3957644A1 (en) 2022-02-23
US11260121B2 (en) 2022-03-01
CN107001428A (zh) 2017-08-01
EP3215520B1 (en) 2022-01-05
CA2967336C (en) 2023-09-26
US10639363B2 (en) 2020-05-05
CA2967336A1 (en) 2016-05-12
AU2015342790B2 (en) 2019-10-03
US11730803B2 (en) 2023-08-22
US20240024452A1 (en) 2024-01-25
US12350326B2 (en) 2025-07-08
WO2018208828A1 (en) 2018-11-15
WO2016073972A1 (en) 2016-05-12
US20210052717A1 (en) 2021-02-25
EP3215520A4 (en) 2018-06-06
CN107001428B (zh) 2023-01-10

Similar Documents

Publication Publication Date Title
JP6731405B2 (ja) ウイルス粒子を用いた癌免疫療法
Lizotte et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
JP7181880B2 (ja) 免疫療法のためのコア／シェル構造プラットホーム
Shukla et al. Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer
US9950025B2 (en) Compositions and methods for treatment of neoplastic disease
EP3347098B1 (en) Targeting mda-5 activation for cancer immunotherapy
JP2010503680A (ja) ヒトｉｌ−１８による調節ｔ細胞のモジュレーション
JP7487892B2 (ja) 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用
CN113924091A (zh) 治疗肿瘤的方法
CN116271090B (zh) 一种具有tlr9激动剂活性的dna纳米笼及其在制备抗肿瘤药物中的应用
US12070478B2 (en) Cancer immunotherapy using virus particles
HK40068065A (en) Cancer immunotherapy using virus particles
EP3592343B1 (en) Cancer immunotherapy using virus particles
HK40068065B (en) Cancer immunotherapy using virus particles
US11590183B2 (en) Cancer immunotherapy using virus particles
CA3019999A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
WO2023200865A2 (en) Cancer therapy
Kim TLR7/8 Agonist Encapsulating Polymeric Nanoparticles for Cancer Immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200706

R150 Certificate of patent or registration of utility model

Ref document number: 6731405

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250